Athena Athena

X

List of Active Pharmaceutical Ingredients (APIs) supplied/manufactured by ICE Pharma

  • Webinars & Exhibitions

  • Chenodeoxycholic Acid

  • Cholic Acid

  • Deoxycholic Acid

  • Ursodeoxycholic Acid

PharmaCompass
ICE S.p.A  RMU
ICE Pharma
Italy Flag
Country
Country
Italy
Address
Address
Via Novi, 78, 15060 Basaluzzo AL
Telephone
Telephone
+39 0522 551250
Twitter
Twitter
Contact Info
Others

ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and inte...
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma also provides contract manufacturing services for liquid and solid finished dosage forms for branded and generic products. Since October 2019, ICE Pharma has been owned by Advent International, one of the largest and most experienced global private equity investors.
ICE S.p.A Company banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and inte...
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma also provides contract manufacturing services for liquid and solid finished dosage forms for branded and generic products. Since October 2019, ICE Pharma has been owned by Advent International, one of the largest and most experienced global private equity investors.
ICE S.p.A Company banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and inte...
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma also provides contract manufacturing services for liquid and solid finished dosage forms for branded and generic products. Since October 2019, ICE Pharma has been owned by Advent International, one of the largest and most experienced global private equity investors.
ICE S.p.A Company banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and inte...
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma also provides contract manufacturing services for liquid and solid finished dosage forms for branded and generic products. Since October 2019, ICE Pharma has been owned by Advent International, one of the largest and most experienced global private equity investors.
ICE S.p.A Company banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and inte...
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma also provides contract manufacturing services for liquid and solid finished dosage forms for branded and generic products. Since October 2019, ICE Pharma has been owned by Advent International, one of the largest and most experienced global private equity investors.
ICE S.p.A Company banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and inte...
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma also provides contract manufacturing services for liquid and solid finished dosage forms for branded and generic products. Since October 2019, ICE Pharma has been owned by Advent International, one of the largest and most experienced global private equity investors.
ICE S.p.A Company banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and inte...
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma also provides contract manufacturing services for liquid and solid finished dosage forms for branded and generic products. Since October 2019, ICE Pharma has been owned by Advent International, one of the largest and most experienced global private equity investors.
ICE S.p.A Company banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
URL Supplier Web Content
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and inte...
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma also provides contract manufacturing services for liquid and solid finished dosage forms for branded and generic products. Since October 2019, ICE Pharma has been owned by Advent International, one of the largest and most experienced global private equity investors.
ICE S.p.A Company banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and inte...
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma also provides contract manufacturing services for liquid and solid finished dosage forms for branded and generic products. Since October 2019, ICE Pharma has been owned by Advent International, one of the largest and most experienced global private equity investors.
ICE S.p.A Company banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and inte...
ICE Pharma's core business includes the manufacture of active pharmaceutical ingredients, the most important of which is Ursodeoxycholic Acid (UDCA), used to treat liver diseases and gallstones. The company develops and manufactures a range of bile acid derivatives that are used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma also provides contract manufacturing services for liquid and solid finished dosage forms for branded and generic products. Since October 2019, ICE Pharma has been owned by Advent International, one of the largest and most experienced global private equity investors.
ICE S.p.A Company banner

Biotechgate Digital

Not Confirmed

envelop Contact Supplier
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY